Biotargeted nanomedicines for cancer: Six tenets before you begin

Michael S. Goldberg, Sara S. Hook, Andrew Z. Wang, Jeff W.M. Bulte, Anil K. Patri, Fatih M. Uckun, Vincent L. Cryns, Justin Hanes, Demir Akin, Jennifer B. Hall, Nastaran Gharkholo, Russell J. Mumper

Research output: Contribution to journalReview articlepeer-review

45 Scopus citations


Biotargeted nanomedicines have captured the attention of academic and industrial scientists who have been motivated by the theoretical possibilities of the 'magic bullet' that was first conceptualized by Paul Ehrlich at the beginning of the 20th century. The Biotargeting Working Group, consisting of more than 50 pharmaceutical scientists, engineers, biologists and clinicians, has been formed as part of the National Cancer Institute's Alliance for Nanotechnology in Cancer to harness collective wisdom in order to tackle conceptual and practical challenges in developing biotargeted nanomedicines for cancer. In modern science and medicine, it is impossible for any individual to be an expert in every aspect of biology, chemistry, materials science, pharmaceutics, toxicology, chemical engineering, imaging, physiology, oncology and regulatory affairs. Drawing on the expertise of leaders from each of these disciplines, this commentary highlights six tenets of biotargeted cancer nanomedicines in order to enable the translation of basic science into clinical practice.

Original languageEnglish (US)
Pages (from-to)299-308
Number of pages10
Issue number2
StatePublished - Feb 2013
Externally publishedYes


  • cost-effectiveness analysis
  • good manufacturing practice
  • ligand
  • nanoparticle
  • receptor targeted

ASJC Scopus subject areas

  • Bioengineering
  • Development
  • General Materials Science
  • Biomedical Engineering
  • Medicine (miscellaneous)


Dive into the research topics of 'Biotargeted nanomedicines for cancer: Six tenets before you begin'. Together they form a unique fingerprint.

Cite this